(Q34619363)

3 August 2017

1 reference

title

Treatment of chronic hepatitis B: case selection and duration of therapy (English)

1 reference

3 August 2017

1 reference

1 reference

Nancy Leung

1

1 reference

3 August 2017

1 April 2002

1 reference

Journal of Gastroenterology and Hepatology

3 August 2017

1 reference

3 August 2017

17

1 reference

3 August 2017

4

1 reference

3 August 2017

409-414

1 reference

Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Biological basis for the clinical use of interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Nucleoside analogues in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Epidemiology of hepatitis B infection in the Western Pacific and South East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Evolving therapies for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02767.X

10.1046/J.1440-1746.2002.02767.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11982721